UnknownPhase 2NCT01914744

Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL

Studying Lymphangioleiomyomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fudan University
Principal Investigator
Ye Guo, MD
Fudan University
Intervention
Entecavir(drug)
Enrollment
82 target
Eligibility
18-80 years · All sexes
Timeline
20132016

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01914744 on ClinicalTrials.gov

Other trials for Lymphangioleiomyomatosis

Additional recruiting or active studies for the same condition.

See all trials for Lymphangioleiomyomatosis

← Back to all trials